Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Sara M Tolaney

Showing results (61-70 of 372) with videos related to

Pageof 38
Sort By:
Critical Reviews in Oncology/Hematology|August 10, 2023
Next-generation antibody-drug conjugates for breast cancer: Moving beyond HER2 and TROP2Ilana Schlam, Ruth Moges, Stefania Morganti, et al.
Immunotargets and Therapy|April 8, 2025
Recent Advances in Immune Checkpoint Inhibitors for Triple-Negative Breast CancerChiara Corti, Beyza Koca, Tasnim Rahman, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|September 10, 2021
Reply to M. Tanaka et alSara M Tolaney, Ann H Partridge, Eric P Winer, et al.
Expert Opinion on Biological Therapy|June 24, 2024
Checkpoint inhibition for early-stage hormone receptor-positive breast cancerIlana Schlam, Chiara Corti, Sarah Sammons, et al.
NPJ Breast Cancer|September 14, 2021
Tissue-agnostic drug approvals: how does this apply to patients with breast cancer?Luiza N Weis, Sara M Tolaney, Carlos H Barrios, et al.
JAMA Oncology|May 28, 2026
Circulating Tumor DNA in Early Breast Cancer: A ReviewIlana Schlam, Sara M Tolaney, Nancy U Lin, et al.
NPJ Breast Cancer|July 30, 2025
Antibody-drug conjugates for treating early-stage breast cancer: current use, anticipated evolutionsPooja Patel, Antonio Giordano, Sara Giordano, et al.
NPJ Breast Cancer|March 23, 2023
The dilemma of selecting a first line CDK4/6 inhibitor for hormone receptor-positive/HER2-negative metastatic breast cancerAlbert Grinshpun, Sara M Tolaney, Harold J Burstein, et al.
Clinical Imaging|October 14, 2017
Occurrence and significance of morphologic changes in patients with metastatic triple negative breast cancer treated with CabozantinibAtul B Shinagare, Bhanusupriya Somarouthu, Hao Guo, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|February 4, 2025
The Mode of Action and Clinical Outcomes of Sacituzumab Govitecan in Solid TumorsSara M Tolaney, Thomas M Cardillo, Chih-Chien Chou, et al.
Pageof 38

Showing results (61-70 of 372) with videos related to

Sort By:
Pageof 38
Critical Reviews in Oncology/Hematology|August 10, 2023
Next-generation antibody-drug conjugates for breast cancer: Moving beyond HER2 and TROP2Ilana Schlam, Ruth Moges, Stefania Morganti, et al.
Immunotargets and Therapy|April 8, 2025
Recent Advances in Immune Checkpoint Inhibitors for Triple-Negative Breast CancerChiara Corti, Beyza Koca, Tasnim Rahman, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|September 10, 2021
Reply to M. Tanaka et alSara M Tolaney, Ann H Partridge, Eric P Winer, et al.
Expert Opinion on Biological Therapy|June 24, 2024
Checkpoint inhibition for early-stage hormone receptor-positive breast cancerIlana Schlam, Chiara Corti, Sarah Sammons, et al.
NPJ Breast Cancer|September 14, 2021
Tissue-agnostic drug approvals: how does this apply to patients with breast cancer?Luiza N Weis, Sara M Tolaney, Carlos H Barrios, et al.
JAMA Oncology|May 28, 2026
Circulating Tumor DNA in Early Breast Cancer: A ReviewIlana Schlam, Sara M Tolaney, Nancy U Lin, et al.
NPJ Breast Cancer|July 30, 2025
Antibody-drug conjugates for treating early-stage breast cancer: current use, anticipated evolutionsPooja Patel, Antonio Giordano, Sara Giordano, et al.
NPJ Breast Cancer|March 23, 2023
The dilemma of selecting a first line CDK4/6 inhibitor for hormone receptor-positive/HER2-negative metastatic breast cancerAlbert Grinshpun, Sara M Tolaney, Harold J Burstein, et al.
Clinical Imaging|October 14, 2017
Occurrence and significance of morphologic changes in patients with metastatic triple negative breast cancer treated with CabozantinibAtul B Shinagare, Bhanusupriya Somarouthu, Hao Guo, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|February 4, 2025
The Mode of Action and Clinical Outcomes of Sacituzumab Govitecan in Solid TumorsSara M Tolaney, Thomas M Cardillo, Chih-Chien Chou, et al.
Pageof 38